LONDON — Corbin’s boys and girls track and field teams took home first place honors in the Cardinal Classic this past week. Corbin’s boys team finished with 157 points while Harlan County (140 points) ...

LOS ANGELES — At the start of the media’s viewing portion for USC’s spring football practice on Tuesday, running back transfers Eli Sanders and Waymond Jordan were seen fielding kick returns. The two ...

This is roughly $800 more than the list price Eli Lilly & Co. charges for its drug, and includes a Hims membership, unlimited consultations with a provider and treatment support, the spokesperson ...

Eli Roth‘s The Horror Section has acquired “Jimmy and Stiggs,” marking the horror company’s first major deal since launching earlier this month, Variety can exclusively report. Directed ...

Eli Lilly has emerged as a popular growth stock thanks to its strength in the weight loss space. But the pharma giant also has an enormous opportunity in the Alzheimer's Disease market. Yet ...

Global pharmaceutical giant Eli Lilly is expanding its footprint in India with a new technology center in Hyderabad as part of its broader strategy to enhance global research and development ...

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.

Mumbai | New Delhi: Pharma major Eli Lilly is open to partnerships with Indian companies to sell its blockbuster anti-diabetes and weight loss drug Mounjaro (tirzepatide), global CEO David Ricks told ...

In the latest trading session, Eli Lilly (LLY) closed at $852.35, marking a -1.45% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.16%. On the other ...

US pharmaceutical giant Eli Lilly has launched Mounjaro (tirzepatide) in India, targeting the country’s $150 billion weight-loss market. This move comes as India faces a rising diabetes crisis, with ...

The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug one step closer to becoming a new, needle-free alternative ...